Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ga-68 PSMA-11 PET in Prostate Cancer Biochemical Recurrence
NCT02918357Phase 3Completed
- Sponsor
- University of California, San Francisco
- Start
- Sep 2016
- Primary completion
- Sep 2017
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gallium ga-68 gozetotide in prostate cancer (PCa), sponsored by University of California, San Francisco. Primary endpoints: Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation at 1 month and Positive Predictive Value (PPV) on a Per-region Basis With Histologic Validation at 1 month. Started Sep 2016; status: completed.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02918357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02918357.